Actively Recruiting
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2022-04-05
1120
Participants Needed
1
Research Sites
436 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate whether segmentectomy had non-inferiority long-term oncological effects (disease-free survival and overall survival) compared with lobectomy in the treatment of patients with early-stage non-small cell lung cancer ≤ 2 cm in the middle third of lung field.
CONDITIONS
Official Title
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18-75 years old
- Tumor size between 6 mm and 20 mm
- Consolidation to tumor ratio (CTR) greater than 0.25 and less than 1
- Tumor center located in the middle third of the lung field
- ECOG performance status of 0, 1, or 2
- Lung function with FEV1 of at least 1 liter and at least 70%
- Both segmentectomy and lobectomy can achieve complete tumor removal (R0 resection)
- No serious heart or lung complications and able to tolerate both surgeries
- No metastasis in hilus pulmonis, mediastinal lymph nodes, or distant sites
- Single tumor nodule or additional nodules smaller than microinvasive tumors
- Provided written informed consent
You will not qualify if you...
- Tumor nodule located in the right middle lobe
- History of other cancers in the last 5 years except early-stage thyroid cancer
- Received preoperative anti-tumor treatments such as chemotherapy, radiation, or targeted therapy
- Serious mental illness
- Pregnant or breastfeeding women
- Congestive heart failure, recent myocardial infarction, or severe coronary artery stenosis within 6 months
- History of stroke or cerebral hemorrhage within 6 months
- Sustained systemic corticosteroid therapy within 1 month
- Predicted surgical margin less than 2 cm or tumor diameter issues on 3D-CT bronchial angiography
- Other conditions deemed unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
Z
Zhihua Li, M.D.
CONTACT
W
Weibing Wu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here